JP Morgan Put 930 REGN 17.05.2024/ DE000JK0U881 /
5/10/2024 2:07:05 PM | Chg.-0.037 | Bid10:00:38 PM | Ask10:00:38 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.006EUR | -86.05% | - Bid Size: - |
- Ask Size: - |
Regeneron Pharmaceut... | 930.00 USD | 5/17/2024 | Put |
GlobeNewswire
5/10
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
5/9
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company P...
GlobeNewswire
5/8
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound G...
GlobeNewswire
5/7
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
GlobeNewswire
4/29
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Mean...
GlobeNewswire
4/25
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing fo...
GlobeNewswire
4/24
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad R...
GlobeNewswire
4/23
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
GlobeNewswire
4/22
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Th...
GlobeNewswire
4/18
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals,...
GlobeNewswire
4/18
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Beh...
GlobeNewswire
4/16
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
GlobeNewswire
4/16
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
GlobeNewswire
4/15
Regeneron Ventures Launches with $500 Million Commitment to Fuel Promising Biotechnology Innovation
GlobeNewswire
4/11
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Phar...
GlobeNewswire
4/7
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in ...
GlobeNewswire
4/1
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and ...
GlobeNewswire
3/22
Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm